Won't be 'same ole, same ole' for ODAC at Perjeta meeting

23:20 EDT 8 Aug 2013 | SCRIP

The FDA said the guidance document was intended to encourage industry innovation and expedite the development of new therapies to treat high-risk early-stage breast cancer, a disease for which there remains a significant unmet medical need in certain...

Original Article: Won't be 'same ole, same ole' for ODAC at Perjeta meeting

NEXT ARTICLE

More From BioPortfolio on "Won't be 'same ole, same ole' for ODAC at Perjeta meeting"

Search BioPortfolio:
Advertisement

Relevant Topic

Top five promising drugs Phase III (November 2013)
Latest News Clinical Trials Research Drugs Reports Corporate
THE FIVE MOST PROMISING DRUGS ENTERING PHASE III TRIALS DRUG DISEASE COMPANY BMN-673 BRCA-mutation-positive breast cancer Biomarin Pharmaceuticals eravacycline Complicated...

Advertisement